WHO Raises Alert Over Acute Scarcity of Weight-Loss Injections
Under one in 10 individuals who could benefit from weight-loss injections like Wegovy can access them, caution the WHO as it publishes its first advice on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging increased and just access to this class of drugs.
Per forecasts, more than two billion are projected to be living with obesity by 2030 without intervention.
"The new guidance recognises that obesity is a long-term condition that can be managed with comprehensive and ongoing treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key barriers to universal access to the jabs that can assist patients in reducing considerable weight, explains the organization.
Weight-Loss Drug Scarcity
Even in the current most optimistic case, the production of these medications would only suffice for approximately 100 million people – less than 10% of the global need, according to the health organization.
The advice encourages nations and manufacturers to expand availability, by approaches such as licensing agreements.
The intellectual property rights on the active ingredient – the primary component of a leading brand – is set to lapse in multiple countries in 2026.
The Way Weight-Loss Drugs Work
The injections mimick a body's own hormone to delay gastric emptying, reduce hunger and boost satiety so people reduce food intake.
Patients typically see weight reduction in the initial weeks of beginning the once-weekly jabs.
Studies indicates users may regain a significant portion a year later of discontinuing the medication, because their usual appetite come back.
Being overweight or obese increases your chance for contracting health problems, such as type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity affects individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, according to the health agency.
